Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sovaldi plus ribavirin in HCV/HIV co-infected patients (PHOTON-1)
NCT01783678Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Jan 2013
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, open-label trial of sofosbuvir in hepatitis C (HCV) (3 arms), sponsored by Gilead Sciences. Primary endpoints: Sustained Virologic Response at 12 Weeks After Discontinuation of Therapy and Incidence of Adverse Events Leading to Permanent Discontinuation of Study Drug at 24 weeks. Started Jan 2013; status: completed.
02
Drugs
sofosbuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01783678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01783678.